{
    "title": "Novartis takes fight to Pfizer's Ibrance with new Kisqali data",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-5061481/Novartis-takes-fight-Pfizers-Ibrance-new-Kisqali-data.html",
    "date": "2017-11-08",
    "keywords": [
        "cancer",
        "breast",
        "drug",
        "growth",
        "novartis",
        "ibrance",
        "approval",
        "kisqali",
        "year",
        "revenue",
        "menopause",
        "premenopausal",
        "miller",
        "effectiveness",
        "drugmaker",
        "turf",
        "latestage",
        "trial",
        "concert",
        "advance",
        "hormonereceptor",
        "factor",
        "therapy",
        "start",
        "dwarfs",
        "thirdquarter",
        "seller",
        "linchpin",
        "plan",
        "treatment",
        "need",
        "disease",
        "prognosis",
        "samit",
        "hirawat",
        "head",
        "development",
        "oncology",
        "kisqalis",
        "use",
        "crowd",
        "cdk46",
        "verzenio",
        "september",
        "december",
        "symposium",
        "antonio",
        "study",
        "bode",
        "legup",
        "absence",
        "safety",
        "qt",
        "prolongation",
        "heart",
        "liver",
        "indication",
        "cdk",
        "inhibitor",
        "competitor",
        "lead",
        "milder",
        "tolerability",
        "profile",
        "baader",
        "helvea",
        "analyst",
        "bruno",
        "editing",
        "michael"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}